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Following acute myocardial infarction (MI), limitation of
infarct size is central to long-term outcome (1). Successful
reperfusion results in smaller infarct size and a marked
reduction in mortality (1,2). However, following fibrinolytic
therapy, ischemic myocardial injury continues during the
process of clot lysis. Although reperfusion arrests the acute
ischemic injury, it may cause further injury (3) and lead to
cell death (4). In addition, successful epicardial reperfusion
may still be associated with a “no reflow” phenomenon at
the myocardial level (5). Hence the need for effective
cardioprotective strategies against ischemic-reperfusion in-
jury. Such strategies may be employed during three key time
intervals—prior to onset of ischemia, following onset of
ischemic injury but prior to reperfusion, and following
reperfusion.
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The feasibility of cardioprotection prior to onset of
ischemia has been well demonstrated by the studies of
ischemic preconditioning—that is, where short periods of
ischemia may precondition the myocardium to withstand a
longer period of ischemia, may slow ischemic injury, and
may limit infarct size (6,7). Two phases of ischemic pre-
conditioning are recognized—an early phase of protection
and a delayed phase of protection lasting up to three days
(7,8). In early preconditioning, endogenous substances are
released including adenosine, bradykinin, and opioid pep-
tides, which bind to myocytes via specific receptors and are
thought to exert their cardioprotective effects by initiating a
complex kinase signaling cascade, leading to opening of the
KATP channel on the mitochondrial inner membrane (7).
Thus, possibilities exist for pharmacological precondition-
ing.
Intermittent administration of an adenosine A1 receptor
agonist has been shown to prolong the delayed phase of
myocardial protection (8). Administration of exogenous
bradykinin is limited by hemodynamic side effects. How-
ever, endogenous bradykinin may theoretically be potenti-
ated by angiotensin-converting enzyme (ACE) inhibitors or
neutral endopeptidase (NEP) inhibitors (7). Opioid precon-
ditioning appears to act via the delta-receptor subtype.
Morphine activates the ,  and  opioid receptors and has
been shown to have cardioprotective properties (9). The
antianginal agent nicorandil, a relatively selective mitochon-
drial KATP channel opener, is currently being evaluated in
the Impact Of Nicorandil in Angina (IONA) study—a
randomized, double-blind, placebo-controlled trial testing
the hypothesis that nicorandil will reduce the incidence of
cardiovascular events in patients with effort angina and
additional risk factors (10).
For patients who present following onset of ischemic
injury but prior to reperfusion, the efficacy of cardioprotec-
tive agents before reperfusion probably depends on drug
access to the ischemic region via some residual culprit artery
flow or via a collateral circulation. Adenosine has been
studied in this setting as an adjunct to fibrinolytic therapy in
the AMISTAD trial (11). Use of adenosine did result in
smaller anterior infarct size, although there was no reduc-
tion in morbidity/mortality (11).
Cardioprotective strategies following reperfusion aim to
limit reperfusion injury, which may contribute as much as
25% to 50% of final infarct size (7). Whereas cell death
during reperfusion may be a continuation of the necrotic
process initiated during the preceding ischemia, apoptosis
(programmed cell death) is now recognized as an additional
mechanism of cell death during ischemia-reperfusion and
may be particularly activated during reperfusion. Inhibitors
of apoptosis by growth factors such as insulin and trans-
forming growth factor-beta1 (TGF-1), or by inhibiting the
caspase cascade (which leads to apoptosis), are currently
being investigated (7). Such a mechanism may partly explain
the apparent benefit of adjunct glucose-insulin-potassium in
patients with MI (12).
A key advance in cardioprotection was elucidation of the
role played by the sodium-hydrogen exchange (NHE)
mechanism in ischemia-reperfusion (13,14). The NHEs
consist of a family of membrane proteins involved in the
transport of protons in exchange for sodium. Six NHE
isoforms have been recognized, with myocyte sarcolemma
composed predominantly of the NHE-1 isoform. The
NHE mechanism is normally a useful protection against
acidosis; however, during ischemia it may be paradoxically
harmful as intracellular accumulation of protons leads to
NHE activation and sodium overload. As the ATP (aden-
osine triphosphate)-dependent Na/K transport system
becomes inoperative during ischemia, the sodium overload
leads to reduced calcium efflux and/or increased calcium
influx via the sodium-calcium exchanger mechanism, result-
ing in intracellular calcium overload. Elevated intracellular
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calcium concentrations cause cell death by several methods
including protease activation, cell contracture, membrane
rupture, and gap junction dysjunction. Successful reperfu-
sion washes out the extracellular metabolites to accelerate
the ionic exchanges, leading to further calcium influx.
In experimental studies NHE-1 inhibitors have been
shown to reduce infarct size when administered before the
onset of ischemia (15) or early after the onset of ischemia
(16). It has also been suggested that NHE inhibition can
minimize microvascular plugging/no-reflow (13,17) and
reduce apoptosis in hearts submitted to an ischemic insult
(18). Several NHE inhibitors have been developed. Most
are amiloride derivatives, including cariporide and enipo-
ride. Three recent clinical trials have assessed these agents in
the setting of ischemia-reperfusion.
Rupprecht et al. (19) studied 100 patients with acute
anterior MI treated with primary percutaneous transluminal
coronary angioplasty (PTCA) who were randomized to
receive placebo (n  51) or 40 mg IV bolus of cariporide
(n  49) before the intervention. At 21-day follow-up,
those receiving cariporide compared with placebo had a
higher ejection fraction by paired left ventriculogram anal-
ysis (50% vs. 40%; p  0.05), lower end-systolic volume
(69.0 vs. 97.0 ml; p  0.05), and improved regional wall
motion indices, including the percentage of chords with
hypokinesis less than 2 SD (p  0.045). In addition,
creatine kinase (CK), creatine kinase-MB fraction (CK-
MB), or lactate dehydrogenase (LDH) release was signifi-
cantly reduced in the cariporide patients.
The GUARd During Ischemia Against Necrosis
(GUARDIAN) trial (20) enrolled a heterogeneous popula-
tion of 11,590 patients with unstable angina or non–ST-
elevation MI or patients undergoing high-risk percutaneous
or surgical revascularization. Patients receiving placebo were
compared with those receiving cariporide (20 mg, 80 mg or
120 mg every 8 h). There was no overall difference in the
primary end point—incidence of death or MI at 36 days.
However, subgroup analysis showed that in those patients
receiving the highest dose (120 mg) a significant reduction
occurred in death or MI in those undergoing bypass surgery
(risk reduction 25%, 95% CI [confidence interval] 3.1% to
41.5%, p  0.03). In addition, Q-wave MI was reduced by
32% (2.6% vs. 1.8%, p  0.03), and non–Q-wave MI was
reduced in those undergoing surgery (7.1% vs. 3.8%, p 
0.005).
In this issue of the Journal, Zeymer et al. (21) present the
results of the Evaluation of the Safety and Cardioprotective
effects of eniporide in Acute Myocardial Infarction (ES-
CAMI) trial. In a dose-ranging phase, 430 patients were
randomized to placebo or eniporide (50, 100, 150 or
200 mg) administered as a 10-min infusion, before the onset
of a reperfusion regimen (fibrinolytic therapy or primary
angioplasty). The primary end point was infarct size esti-
mated by area under the release curve of -hydroxybutyrate
dehydrogenase from 0 to 72 h. Significant reductions in
enzyme release were noted in patients receiving 100 mg or
150 mg eniporide compared with placebo, particularly in the
primary angioplasty subgroup. These doses were thus eval-
uated in a larger dose-confirmation phase (959 patients).
Unfortunately, there was no difference in enzymatic infarct
size among the three groups (placebo, eniporide 100 mg,
eniporide 150 mg) nor any difference in secondary end
points including major adverse clinical events and ST-
segment resolution. Subgroup analysis showed that patients
receiving 150 mg eniporide who reperfused late (4 h after
onset of pain) appeared to derive a small benefit from
adjunct eniporide with respect to enzymatic infarct size and
incidence of heart failure (Killip class 2) at one week.
However, given the modest number of patients in this
subgroup, such benefit should be interpreted with caution.
Thus, despite promising preclinical findings, the clinical
trials did not support the hypothesis that NHE-1 inhibition
with cariporide or eniporide prevented the progression from
ischemic injury to necrosis. What reasons might account for
the disparity between preclinical and clinical findings?
First, although in preclinical evaluation there was clear
evidence of benefit when administration occurred before the
onset of ischemia, the evidence for benefit following the
onset of ischemia or following reperfusion was less clear
(7,15). It has been shown that, in the initial minutes
following the onset of ischemia, voltage-gated sodium
channels constitute a major port of sodium entry (22). With
falling intracellular pH, the NHE mechanism is activated
and forms the dominant influx pathway over the next
30 min of ischemia. However, in the later course of
ischemia, the NHE mechanism is partially inactivated (22).
Thus, NHE inhibition would appear to be best adminis-
tered prior to or early after the onset of ischemia. In the
GUARDIAN trial, benefit was achieved when cariporide
was given before coronary artery bypass graft surgery
(CABG)—such patients undergo a scheduled ischemic
arrest of limited and predictable duration.
Second, the optimum dose for NHE inhibition in hu-
mans is not yet clear, although the GUARDIAN trial
would suggest that, given the favorable safety profile, near
complete NHE inhibition is desirable. Larger doses may be
required if administered after coronary occlusion but before
reperfusion, as drug delivery to the subtended myocardium
is likely to be unreliable. In contrast, in the ESCAMI trial,
there was a nonsignificant trend toward excess deaths,
particularly in the 200 mg eniporide group. This is most
likely to have been a chance finding given the small
numbers. However, it does suggest the need for a little
caution with high doses in future eniporide dose-ranging
trials. Zoniporide, a novel NHE-1 inhibitor, 2.5 to 20 times
more potent than cariporide or eniporide, is currently
undergoing preclinical evaluation (23).
Third, the optimal duration of administration also re-
quires evaluation. The availability of an oral NHE-1 inhib-
itor (13) raises the possibility of an extended treatment
window for patients presenting with unstable angina and at
increased risk of subsequent infarction.
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In summary, optimization of cardioprotection strategies
continues to represent a challenge. The NHE-1 inhibitors
have a clear potential when administered before or early
after onset of ischemia, although their role in treatment of
established ischemia or for prevention of reperfusion injury
is less certain. Other potential cardioprotective strategies
include antioxidants and free radical scavengers, anti-
integrins, antiselectins, anticytokines, and anti-C5 comple-
ment. Ultimately it is likely that a combination of cardio-
protective agents will be required to address individual
components of the ischemia-reperfusion sequence ade-
quately.
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